 Injections, Subcutaneous
"Injections, Subcutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
| Descriptor ID |
D007279
|
| MeSH Number(s) |
E02.319.267.530.620
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Injections, Subcutaneous".
Below are MeSH descriptors whose meaning is more specific than "Injections, Subcutaneous".
This graph shows the total number of publications written about "Injections, Subcutaneous" by people in this website by year, and whether "Injections, Subcutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1988 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1996 | 0 | 2 | 2 | | 1998 | 0 | 3 | 3 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 4 | 4 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 3 | 3 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 4 | 4 | | 2015 | 0 | 3 | 3 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Injections, Subcutaneous" by people in Profiles.
-
Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, Purington N, Kamble S, de Vries CR, Quintero O, Feng K, Ley C, Winslow D, Newberry J, Edwards K, Hislop C, Choong I, Maldonado Y, Glenn J, Bhatt A, Blish C, Wang T, Khosla C, Pinsky BA, Desai M, Parsonnet J, Singh U. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021 03 30; 12(1):1967.
-
Iida S, Ishikawa T, Min CK, Kim K, Yeh SP, Usmani SZ, Mateos MV, Nahi H, Heuck C, Qin X, Parasrampuria DA, Gries KS, Qi M, Bahlis N, Ito S. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. Ann Hematol. 2021 Apr; 100(4):1065-1077.
-
Struyvenberg MR, Fong ZV, Martin CR, Tseng JF, Clancy TE, Fernández-Del Castillo C, Tillman HJ, Bellin MD, Freedman SD. Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms After Total Pancreatectomy. Pancreas. 2017 Oct; 46(9):1188-1195.
-
Salameh JS, Deeb W, Burawski L, Wright S, Souayah N. Safety and Efficacy of Subcutaneous Immunoglobulin in the Treatment of Neuromuscular Disorders. J Clin Neuromuscul Dis. 2016 Mar; 17(3):110-9.
-
Specht CA, Lee CK, Huang H, Tipper DJ, Shen ZT, Lodge JK, Leszyk J, Ostroff GR, Levitz SM. Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts. MBio. 2015 Dec 22; 6(6):e01905-15.
-
Walenbergh SM, Houben T, Hendrikx T, Jeurissen ML, van Gorp PJ, Vaes N, Olde Damink SW, Verheyen F, Koek GH, Lütjohann D, Grebe A, Latz E, Shiri-Sverdlov R. Weekly Treatment of 2-Hydroxypropyl-ß-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice. Int J Mol Sci. 2015; 16(9):21056-69.
-
Huang W, Tam K, Fernando J, Heffernan M, King J, DiFranza JR. Nicotine and Resting-State Functional Connectivity: Effects of Intermittent Doses. Nicotine Tob Res. 2015 Nov; 17(11):1311-7.
-
Rees DG, Phillpotts RJ, Griffin KF, Lukaszewski RA, Laws TR, Atkins HS, Krieg AM, Titball RW. CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. Int J Antimicrob Agents. 2013 Dec; 42(6):587-8.
-
Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8.
-
Knight JS, Zhao W, Luo W, Subramanian V, O'Dell AA, Yalavarthi S, Hodgin JB, Eitzman DT, Thompson PR, Kaplan MJ. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest. 2013 Jul; 123(7):2981-93.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|